Calidi Biotherapeutics Secures $3.9 Million in Funding Through Direct Offering and Private Placement
Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a clinical-stage biotechnology company specializing in innovative immunotherapies, has concluded a $3.9 million fundraising initiative. This funding was achieved...
